Kalaris Therapeutics KLRS
NASDAQ KLRS
$2.12 +0.05 (+2.54%)
As of: Oct 21, 2026 · 9:44 AM EDT

Kalaris Therapeutics (KLRS) Non-Current Debt (2024 - 2025)

Updated

Analysis

Kalaris Therapeutics (KLRS) Non-Current Debt (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,128.06 Bn 1,096.64 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 615.47 Bn 534.00 Bn 17.26 Bn 37.34 Bn
3 AbbVie 504.80 Bn 477.91 Bn 12.70 Bn 62.48 Bn
4 Merck 368.45 Bn 322.83 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 298.44 Bn 262.43 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.92 Bn 235.60 Bn 12.86 Bn 23.68 Bn
7 Amgen 236.10 Bn 191.50 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 190.71 Bn 164.91 Bn 6.22 Bn 23.83 Bn
9 Pfizer 170.16 Bn 116.81 Bn 10.94 Bn 60.50 Bn
10 Kalaris Therapeutics 50.45 Mn -43.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 7.50 Mn
Dec 31, 2024 9.97 Mn
Jun 30, 2024 5.00 Mn
Mar 31, 2024 4.99 Mn
API Access

Kalaris Therapeutics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=KLRS&period=max&api_key=YOUR_API_KEY